LMB-100 is a lab-created protein that targets mesothelin. It is being tested against pancreatic cancer and other solid tumors in a clinical trial.
Rexahn Pharmaceuticals is testing RX-3117, a slow-releasing drug similar to gemcitabine, in a clinical trial for metastatic pancreatic cancer patients.
Dr. Alok Khorana discusses the results of clinical trials of neoadjuvant chemotherapy and radiation to make surgery more effective.
Dr. John Chabot explains that more pancreatic cancer patients may qualify for surgery if they consult an experience pancreatic surgical team.
Dr. Robert Vonderheide of the Abramson Cancer Center at the University of Pennsylvania describes immunotherapy trials for pancreatic cancer.